Analysts’ Weekly Ratings Updates for Axsome Therapeutics (AXSM)

A number of research firms have changed their ratings and price targets for Axsome Therapeutics (NASDAQ: AXSM):

• 6/17/2026 – Axsome Therapeutics had its price target raised by TD Cowen from $275.00 to $300.00. They now have a “buy” rating on the stock.
• 6/15/2026 – Axsome Therapeutics was upgraded by Truist Financial Corporation to “strong-buy”.
• 6/11/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $380.00 price target on the stock.
• 6/11/2026 – Axsome Therapeutics was upgraded by Morgan Stanley from “reduce” to “overweight”.
• 6/4/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 5/5/2026 – Axsome Therapeutics was given a new $280.00 price target by Deutsche Bank Aktiengesellschaft.
• 5/5/2026 – Axsome Therapeutics had its price target raised by Needham & Company LLC from $225.00 to $255.00. They now have a “buy” rating on the stock.
• 5/5/2026 – Axsome Therapeutics had its price target raised by Royal Bank Of Canada from $242.00 to $302.00. They now have an “outperform” rating on the stock.
• 5/5/2026 – Axsome Therapeutics had its price target raised by HC Wainwright from $270.00 to $290.00. They now have a “buy” rating on the stock.
• 5/5/2026 – Axsome Therapeutics had its price target raised by Morgan Stanley from $217.00 to $242.00. They now have an “equal weight” rating on the stock.
• 5/5/2026 – Axsome Therapeutics had its price target raised by Wells Fargo & Company from $225.00 to $255.00. They now have an “overweight” rating on the stock.
• 5/5/2026 – Axsome Therapeutics had its price target raised by Mizuho from $228.00 to $310.00. They now have an “outperform” rating on the stock.
• 5/5/2026 – Axsome Therapeutics had its price target raised by Robert W. Baird from $241.00 to $246.00. They now have an “outperform” rating on the stock.
• 5/4/2026 – Axsome Therapeutics was given a new $280.00 price target by Oppenheimer Holdings, Inc..
• 5/4/2026 – Axsome Therapeutics had its price target raised by Guggenheim from $245.00 to $260.00. They now have a “buy” rating on the stock.
• 5/4/2026 – Axsome Therapeutics had its “overweight” rating reaffirmed by Piper Sandler. They now have a $258.00 price target on the stock.
• 5/4/2026 – Axsome Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $272.00 price target on the stock.
• 5/4/2026 – Axsome Therapeutics had its price target raised by Jefferies Financial Group Inc. from $245.00 to $275.00. They now have a “buy” rating on the stock.
• 5/4/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $281.00 price target on the stock.
• 5/4/2026 – Axsome Therapeutics had its price target raised by HC Wainwright from $260.00 to $270.00. They now have a “buy” rating on the stock.
• 5/1/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by TD Cowen.
• 5/1/2026 – Axsome Therapeutics had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $250.00 price target on the stock.
• 5/1/2026 – Axsome Therapeutics had its price target raised by Needham & Company LLC from $225.00 to $255.00. They now have a “buy” rating on the stock.
• 4/30/2026 – Axsome Therapeutics was given a new $217.00 price target by Morgan Stanley.

Insiders Place Their Bets

In other news, CFO Nick Pizzie sold 33,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $240.09, for a total transaction of $7,922,970.00. Following the transaction, the chief financial officer directly owned 42,867 shares of the company’s stock, valued at approximately $10,291,938.03. This trade represents a 43.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Mark L. Jacobson sold 4,517 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $227.94, for a total value of $1,029,604.98. Following the completion of the sale, the chief operating officer owned 4,517 shares of the company’s stock, valued at $1,029,604.98. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 113,686 shares of company stock worth $26,666,006. 20.60% of the stock is owned by company insiders.

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.